Search
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpiv...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated b...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLedipasvir
go.drugbank.com/drugs/DB09027ApprovedLedipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or wi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMiltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and ...
Categories: P-glycoprotein substratesNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult pati...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigationalOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in c...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalOlodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates